Crossmark

Discovery of oncogenic <i>ROS1</i> missense mutations with sensitivity to tyrosine kinase inhibitors

Crossref DOI link: https://doi.org/10.15252/emmm.202217367

Published Online: 2023-08-17

Published Print: 2023-10-11

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Iyer, Sudarshan R https://orcid.org/0000-0001-7837-1854
Nusser, Kevin

Jones, Kristen

Shinde, Pushkar

Keddy, Clare https://orcid.org/0000-0001-5083-7296
Beach, Catherine Z https://orcid.org/0000-0003-0750-3658
Aguero, Erin

Force, Jeremy

Shinde, Ujwal

Davare, Monika A https://orcid.org/0000-0003-1802-7597
Funding

Funding for this research was provided by:

National Institutes of Health (F30CA247253)

National Institutes of Health (R01CA233495)

Knight Cancer Institute, Oregon Health and Science University (APEDI1366)
License Information

Version of Record valid from 2023-08-17
More Information

Publication History

Received: 2022-12-27

Accepted: 2023-07-26

Published: 2023-08-17